VK2735
Evidence: B — Meaningful Human EvidenceEvidence: DGrade B — SC -- one peer-reviewed Phase 2 RCT, RETRACTION_CLEAR on direct Crossref check, two Phase 3 trials enrolled but not read out. Oral -- Phase 2 topline only, not peer-reviewed; excluded from this grade..
Grade D — Oral VK2735 program (VENTURE-Oral).
Phase 2 topline reported by sponsor only, no peer-reviewed publication as of this review.
Metabolic / Weight Management
Evidence Snapshot
What this grade covers
SC -- one peer-reviewed Phase 2 RCT, RETRACTION_CLEAR on direct Crossref check, two Phase 3 trials enrolled but not read out. Oral -- Phase 2 topline only, not peer-reviewed; excluded from this grade.
Regulatory Context
VK2735 is investigational; no approval was identified in the verified searches used for this review in any jurisdiction. Two Phase 3 trials are underway: VANQUISH-1 (SC, obesity/overweight without diabetes, NCT07104500) and VANQUISH-2 (SC, obesity/overweight with type 2 diabetes, NCT07104383); neither has reported results.
Research Takeaway
VK2735 is an engineered peptide that acts as a dual agonist at the GIP receptor and the GLP-1 receptor. It is studied in both subcutaneous injectable and oral tablet formulations, confirmed by the sponsor to be the same molecule/program in different delivery formats.
Evidence boundary: Do not describe VK2735 as chemically/structurally identical to tirzepatide -- they are distinct molecules sharing a receptor pair.
See all 5 evidence claims →Quick Summary
VK2735 is an engineered peptide developed by Viking Therapeutics that acts as a dual agonist at the GIP receptor and the GLP-1 receptor. In a 13-week Phase 2 trial, subcutaneous VK2735 produced dose-dependent weight loss of up to 14.7% versus 1.7% with placebo. An oral tablet formulation has reported topline (not yet peer-reviewed) results of up to 12.2% weight loss. VK2735 is investigational, with two Phase 3 subcutaneous trials underway. It shares a receptor-targeting pair with tirzepatide but is a distinct molecule; no evidence transfer between the two is permitted.
Mechanism & Research Overview
VK2735 is an engineered peptide that acts as a dual agonist at the GIP receptor and the GLP-1 receptor. It shares a receptor-targeting pair with tirzepatide but is a distinct molecule with its own separate clinical trials; no efficacy, safety, dosing, or regulatory data may be transferred between them.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
VK2735 is an engineered peptide that acts as a dual agonist at the GIP receptor and the GLP-1 receptor. It is studied in both subcutaneous injectable and oral tablet formulations, confirmed by the sponsor to be the same molecule/program in different delivery formats.
Does not establish
Evidence boundary: Do not describe VK2735 as chemically/structurally identical to tirzepatide -- they are distinct molecules sharing a receptor pair.
Sources: Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study; VK2735 for Weight Management Phase 2 (VENTURE-Oral Dosing)
Supported
In a 13-week Phase 2 RCT, SC VK2735 (2.5-15mg weekly) produced dose-dependent mean body-weight reductions of 9.1% to 14.7% versus 1.7% with placebo; 93% of active-arm participants achieved at least 5% weight loss, versus 12% on placebo.
Does not establish
Evidence boundary: 13-week duration only; no longer-term SC efficacy data exists yet.
Supported
In the same 13-week SC trial, the most common treatment-related adverse events were nausea (36.6%), constipation (21.1%), and vomiting (12.6%); 8.5% of participants discontinued due to adverse events; no Grade 4/5 events occurred.
Does not establish
Evidence boundary: Route-specific to SC -- do not merge with oral tolerability data.
Supported
A separate 13-week Phase 2 trial of oral VK2735 tablets reported, via company announcement only (not yet peer-reviewed), mean weight loss of up to 12.2% versus 1.3% with placebo; this figure is company-reported and has not been confirmed in a peer-reviewed publication.
Does not establish
Evidence boundary: Do not present as peer-reviewed-confirmed; always label company-reported.
Sources: VK2735 for Weight Management Phase 2 (VENTURE-Oral Dosing)
Supported
VK2735 is investigational; no approval was identified in the verified searches used for this review in any jurisdiction. Two Phase 3 trials are underway: VANQUISH-1 (SC, obesity/overweight without diabetes, NCT07104500) and VANQUISH-2 (SC, obesity/overweight with type 2 diabetes, NCT07104383); neither has reported results.
Does not establish
Evidence boundary: An earlier reference to a different ClinicalTrials.gov identifier for VANQUISH-1 was incorrect and has been corrected. NCT07104500 is the verified VANQUISH-1 registration; no other trial identifier should be used for this study.
Sources: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management (VANQUISH-1); VANQUISH-2: Phase 3 study of SC VK2735 in adults with obesity/overweight and type 2 diabetes
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The most common adverse events reported with SC VK2735 were nausea, constipation, and vomiting; 8.5% of participants discontinued treatment due to adverse events over 13 weeks.Safety Consideration
Oral VK2735's tolerability has only been described in a company announcement (not yet peer-reviewed); it should not be presented as an established, peer-reviewed-confirmed safety profile.Safety Consideration
VK2735 shares a receptor-targeting pair (GIP/GLP-1) with tirzepatide, an approved medicine; shared receptor targeting does not mean shared adverse-event rates, and no tirzepatide safety data may be used to describe VK2735's risk profile.
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study (2026):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study | 2026 | 176 adults (174 mITT) with obesity/overweight plus at least one comorbidity, non-diabetic, BMI<=50 | Dose-dependent weight loss of -9.1% (2.5mg) to -14.7% (15mg) vs -1.7% with placebo; 93% of active-arm participants achieved at least 5% weight loss versus 12% on placebo.
| Nausea 36.6% (range 26-63% by dose), constipation 21.1% (range 20-29%), vomiting 12.6% overall (range 9-29% by dose); discontinuation-for-adverse-event 8.5% (15/176); no Grade 4/5 events. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management (VANQUISH-1) | 2026 | Approximately 4,500-4,650 adults with obesity/overweight, without diabetes | Development-status only: active, not recruiting; no results yet. An earlier reference to a different ClinicalTrials.gov identifier for this trial was incorrect and has been corrected; NCT07104500 is the verified VANQUISH-1 registration.
| ||
| VANQUISH-2: Phase 3 study of SC VK2735 in adults with obesity/overweight and type 2 diabetes | 2026 | Approximately 1,000-1,100 adults with obesity/overweight and type 2 diabetes | Development-status only: no results yet. This will be the future source for any T2D-indication efficacy claim for VK2735 -- none exists yet.
| ||
| VK2735 for Weight Management Phase 2 (VENTURE-Oral Dosing) | 2025 | 280 adults with obesity (BMI>=30) or overweight (BMI>=27) plus at least one comorbidity | Registry-confirmed Phase 2 trial of the oral tablet formulation. A company press release (Aug 19, 2025, reiterated at ECO 2026) reports topline, NOT yet peer-reviewed results: up to 12.2% (26.6 lb) mean weight loss vs 1.3% (2.9 lb) placebo at 13 weeks; nausea 58%, vomiting 26%, discontinuation-for-adverse-event 28% (VK2735) vs 18% (placebo). This is company-reported only -- no peer-reviewed oral publication exists as of this review; do not present as peer-reviewed-confirmed.
|
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and company announcements and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for VK2735
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.